India · Delayed Price · Currency is INR NSE:NEPHROPLUS Statistics
Total Valuation
NSE:NEPHROPLUS has a market cap or net worth of INR 62.86 billion. The enterprise value is 59.40 billion.
| Market Cap | 62.86B |
| Enterprise Value | 59.40B |
Important Dates
The next estimated earnings date is Friday, July 24, 2026.
| Earnings Date | Jul 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NSE:NEPHROPLUS has 100.34 million shares outstanding. The number of shares has increased by 23.08% in one year.
| Current Share Class | 100.34M |
| Shares Outstanding | 100.34M |
| Shares Change (YoY) | +23.08% |
| Shares Change (QoQ) | +6.61% |
| Owned by Insiders (%) | 14.75% |
| Owned by Institutions (%) | 20.70% |
| Float | 28.37M |
Valuation Ratios
The trailing PE ratio is 77.35 and the forward PE ratio is 38.54. NSE:NEPHROPLUS's PEG ratio is 0.87.
| PE Ratio | 77.35 |
| Forward PE | 38.54 |
| PS Ratio | 6.29 |
| PB Ratio | 5.63 |
| P/TBV Ratio | 6.31 |
| P/FCF Ratio | 55.32 |
| P/OCF Ratio | 27.03 |
| PEG Ratio | 0.87 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 26.47, with an EV/FCF ratio of 52.27.
| EV / Earnings | 77.31 |
| EV / Sales | 5.95 |
| EV / EBITDA | 26.47 |
| EV / EBIT | 43.76 |
| EV / FCF | 52.27 |
Financial Position
The company has a current ratio of 2.80, with a Debt / Equity ratio of 0.07.
| Current Ratio | 2.80 |
| Quick Ratio | 2.48 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.35 |
| Debt / FCF | 0.70 |
| Interest Coverage | 2.40 |
Financial Efficiency
Return on equity (ROE) is 9.04% and return on invested capital (ROIC) is 14.19%.
| Return on Equity (ROE) | 9.04% |
| Return on Assets (ROA) | 7.03% |
| Return on Invested Capital (ROIC) | 14.19% |
| Return on Capital Employed (ROCE) | 11.85% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 4.35M |
| Profits Per Employee | 334,961 |
| Employee Count | 3,448 |
| Asset Turnover | 0.81 |
| Inventory Turnover | 20.77 |
Taxes
In the past 12 months, NSE:NEPHROPLUS has paid 206.34 million in taxes.
| Income Tax | 206.34M |
| Effective Tax Rate | 21.17% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 655.23 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 39.80 |
| Average Volume (20 Days) | 194,003 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:NEPHROPLUS had revenue of INR 9.99 billion and earned 768.40 million in profits. Earnings per share was 8.10.
| Revenue | 9.99B |
| Gross Profit | 3.79B |
| Operating Income | 1.39B |
| Pretax Income | 974.74M |
| Net Income | 768.40M |
| EBITDA | 2.14B |
| EBIT | 1.39B |
| Earnings Per Share (EPS) | 8.10 |
Balance Sheet
The company has 4.26 billion in cash and 797.07 million in debt, with a net cash position of 3.46 billion or 34.47 per share.
| Cash & Cash Equivalents | 4.26B |
| Total Debt | 797.07M |
| Net Cash | 3.46B |
| Net Cash Per Share | 34.47 |
| Equity (Book Value) | 11.16B |
| Book Value Per Share | 111.27 |
| Working Capital | 5.40B |
Cash Flow
In the last 12 months, operating cash flow was 2.33 billion and capital expenditures -1.19 billion, giving a free cash flow of 1.14 billion.
| Operating Cash Flow | 2.33B |
| Capital Expenditures | -1.19B |
| Depreciation & Amortization | 752.05M |
| Net Borrowing | -2.15B |
| Free Cash Flow | 1.14B |
| FCF Per Share | 11.33 |
Margins
Gross margin is 37.98%, with operating and profit margins of 13.90% and 7.69%.
| Gross Margin | 37.98% |
| Operating Margin | 13.90% |
| Pretax Margin | 9.76% |
| Profit Margin | 7.69% |
| EBITDA Margin | 21.43% |
| EBIT Margin | 13.90% |
| FCF Margin | 11.38% |
Dividends & Yields
NSE:NEPHROPLUS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.08% |
| Shareholder Yield | -23.08% |
| Earnings Yield | 1.22% |
| FCF Yield | 1.81% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for NSE:NEPHROPLUS is 771.25, which is 22.65% higher than the current price. The consensus rating is "Buy".
| Price Target | 771.25 |
| Price Target Difference | 22.65% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 17.77% |
| EPS Growth Forecast (3Y) | 43.89% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NSE:NEPHROPLUS has an Altman Z-Score of 10.36 and a Piotroski F-Score of 8.
| Altman Z-Score | 10.36 |
| Piotroski F-Score | 8 |